Oxaliplatina Mylan

Oxaliplatin, the active ingredient in Oxaliplatina Mylan, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in combination regimens to treat certain solid tumours, most notably colorectal cancer, in adult patients. GNH USA supplies Oxaliplatina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic that targets the DNA replication pathway in malignant cells.

- Colorectal cancer: used as part of the FOLFOX regimen to shrink tumour burden and improve survival. - Gastric cancer: combined with other agents to enhance response rates. - Pancreatic cancer: incorporated in multi‑drug protocols to increase tumour control. - Ovarian cancer: used in selected regimens to achieve disease stabilization. - Advanced solid tumours: employed in off‑label clinical trials to explore efficacy.

Oxaliplatin may elicit a range of adverse reactions, from mild to severe, depending on patient factors and treatment context.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset during infusion. - Peripheral neuropathy: tingling or numbness in the hands and feet, often dose‑related. - Diarrhoea: loose stools that may require supportive care. - Fatigue: generalized tiredness common during chemotherapy cycles. - Thrombocytopenia: reduced platelet count increasing bleeding risk.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical intervention. - Acute hemolytic anemia: rapid destruction of red blood cells. - Pulmonary toxicity: interstitial lung disease presenting with cough and dyspnoea. - Cardiac arrhythmias: irregular heart rhythms observed during infusion. - Neutropenic sepsis: life‑threatening infection due to low neutrophil counts.

When using Oxaliplatin, clinicians should assess patient history and monitor laboratory parameters throughout therapy.

- Renal function: adjust dosing or avoid use in severe impairment. - Pre‑existing neuropathy: evaluate risk of worsening peripheral symptoms. - Hepatic dysfunction: monitor liver enzymes and consider dose modification. - Hematologic status: check complete blood counts before each cycle. - Concomitant ototoxic drugs: avoid or closely monitor auditory function. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Oxaliplatin may interact with several concomitant medications, altering efficacy or safety.

Major Interactions (Avoid): - Aminoglycoside antibiotics: increased risk of nephrotoxicity. - High‑dose vitamin C: may reduce platinum‑drug cytotoxicity. - Live vaccines: immunosuppression can diminish vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk due to thrombocytopenia. - NSAIDs: potential for additive gastrointestinal irritation. - CYP‑mediated drugs: minor alterations in drug metabolism observed.